Below is a list of causes of macrocephaly from Swaimans Pediatric Neurology: Principles and Practice noted in The Little Black Book of Neurology:

Hydrocephalus
Noncommunicating
Arnold–Chiari malformation
Aqueductal stenosis
X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS) syndrome (L1CAM)
Dandy–Walker malformation
Galenic vein aneurysm or malformation
Neoplasms, supratentorial, and infratentorial
Arachnoid cyst, infratentorial
Holoprosencephaly with dorsal interhemispheric sac

Communicating
External or extraventricular obstructive hydrocephalus (dilated subarachnoid space)

Arachnoid cyst, supratentorial
Meningeal fibrosis/obstruction
Postinflammatory
Posthemorrhagic
Neoplastic infiltration

Vascular
Arteriovenous malformation
Intracranial hemorrhage
Dural sinus thrombosis

Choroid plexus papilloma
Neurocutaneous syndromes
Incontinentia pigmenti

Destructive lesions
Hydranencephaly
Porencephaly

Familial, autosomal-dominant, autosomal-recessive, X-linked
Subdural fluid
Hematoma
Hygroma
Empyema

Brain edema (toxic-metabolic)
Intoxication
Lead
Vitamin A
Tetracycline
Endocrine (hypoparathyroidism, hypoadrenocorticism)
Galactosemia
Idiopathic (pseudotumorcerebri)

Thick skull or scalp (hyperostosis)
Familial variation
Anemia
Osteoporosis, severe precocious autosomal-recessive osteoporosis (CLCN7, TCIRG1)
Pycnodysostosis (CTSK)
Craniometaphyseal dysplasia (ANKH)
Craniodiaphyseal dysplasia
Pyle dysplasia
Sclerosteosis (SOST)
Juvenile Paget disease
Idiopathic hyperphosphatasia
Familial osteoectasia
Osteogenesis imperfecta
Rickets
Cleidocranial dysostosis
Hyperostosis corticalis generalisata (van Buchem disease)
Proteus syndrome

Megalencephaly and hemimegalencephaly
Diagnosis
Macrocephaly is customarily diagnosed if head circumference is greater than two standard deviations (SDs) above the mean. Relative macrocephaly occurs if the measure is less than two SDs above the mean, but is disproportionately above that when ethnicity and stature are considered. Diagnosis can be determined in utero or can be determined within 18–24 months after birth in some cases where head circumference tends to stabilize in infants. Diagnosis in infants includes measuring the circumference of the childs head and comparing how significant it falls above the 97.5 percentile of children similar to their demographic. If falling above the 97.5th percentile then the patient will be checked to determine whether there is any intracranial pressure present and whether or not immediate surgery is needed.
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.Dacomitinib has advanced to several Phase III clinical trials. The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing.In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.Dacomitinib was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019, for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation. References
External links
"Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.